Discovery of Potent Antagonists of the Interaction between Human Double Minute 2 and Tumor Suppressor p53

2000 ◽  
Vol 43 (17) ◽  
pp. 3205-3208 ◽  
Author(s):  
Carlos García-Echeverría ◽  
Patrick Chène ◽  
Marcel J. J. Blommers ◽  
Pascal Furet
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor P53 ◽  
Double Minute

scholarly journals Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors

2021 ◽  
Author(s):  
Anselm Schneider ◽  
Jörg Kallen ◽  
Johannes Ottl ◽  
Patrick C Reid ◽  
Sebastien Ripoche ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Peptide Inhibitors ◽  
Negative Regulator ◽  
Tumor Suppressor P53 ◽  
X Ray ◽  
Mouse Double Minute ◽  
Double Minute ◽  
Important Negative Regulator ◽  
Display Technique ◽  
Macrocyclic Peptide

Mouse double minute 2 homolog (MDM2, Hdm2) is an important negative regulator of the tumor suppressor p53. Using a mRNA based display technique to screen a library of >1012 in...

Dense Liquid Condensates Host the Nucleation of Tumor Suppressor p53 Fibrils

2018 ◽  
Author(s):  
Mohammad S. Safari ◽  
Zhiqing Wang ◽  
Kunaal Tailor ◽  
Anatoly B. Kolomeisky ◽  
Jacinta C. Conrad ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor P53 ◽  
Dense Liquid

The Sumoylation Modulated Tumor Suppressor p53 Regulates Cell Cycle Checking Genes to Mediate Lens Differentiation

2019 ◽  
Vol 18 (8) ◽  
pp. 556-565 ◽  
Author(s):  
Xiangcheng Tang ◽  
Zhigang Chen ◽  
Mi Deng ◽  
Ling Wang ◽  
Qian Nie ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Tumor Suppressor ◽  
Tumor Suppressor P53

MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)

2020 ◽  
Vol 14 (4) ◽  
pp. 324-369 ◽  
Author(s):  
Rafał Rusiecki ◽  
Jakub Witkowski ◽  
Joanna Jaszczewska-Adamczak
Keyword(s):  
Therapeutic Potential ◽  
Research Work ◽  
Academic Research ◽  
Tumor Suppressor P53 ◽  
Research Groups ◽  
Current State ◽  
Mouse Double Minute ◽  
Patent Review ◽  
Main Emphasis ◽  
Double Minute

Background: Mouse Double Minute 2 protein (MDM2) is a cellular regulator of p53 tumor suppressor (p53). Inhibition of the interaction between MDM2 and p53 proteins is a promising anticancer therapy. Objective: This updated patent review is an attempt to compile the research and achievements of the various researchers working on small molecule MDM2 inhibitors from 2010 to date. We provide an outlook into the future for therapy based on MDM2 inhibition by presenting an overview of the most relevant patents which have recently appeared in the literature. Methods: Literature and recent patents focusing on the anticancer potential of MDM2-p53 interaction inhibitors and its applications have been analyzed. We put the main emphasis on the most perspective compounds which are or were examined in clinical trials. Results: Literature data indicated that MDM2 inhibitors are therapeutically effective in specific types of cancer or non-cancer diseases. A great number of patents and research work around new MDM2- p53 interaction inhibitors, possible combinations, new indications, clinical regimens in previous years prove that this targeted therapy is in the scope of interest for many business and academic research groups. Conclusion: Novel MDM2 inhibitors thanks to higher potency and better ADME properties have shown effectiveness in preclinical and clinical development however the final improvement of therapeutic potential for MDM2 inhibitors might depend on the useful combination therapy and exploring new cancer and non-cancer indications.

p22/PACAP Response Gene 1 (PRG1): A Putative Target Gene for the Tumor Suppressor p53

1998 ◽  
Vol 865 (1 VIP, PACAP, A) ◽  
pp. 27-36 ◽  
Author(s):  
HEINER SCHAFER ◽  
ANNA TRAUZOLD ◽  
THORSTEN SEBENS ◽  
WOLFGANG DEPPERT ◽  
ULRICH R. FOLSCH ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Target Gene ◽  
Tumor Suppressor P53 ◽  
Putative Target Gene ◽  
Response Gene ◽  
Putative Target
Sign in / Sign up

Export Citation Format

Share Document